Review on IRF4, with data on DNA/RNA, on the protein encoded and where the gene is implicated.
Expression
IRF4 protein is expressed predominantly in blood cells. However, its expression can also be detected in adipocytes and melanocytes. In blood cells, expression of IRF4 can be detected in T, B, DC and macrophages. Expression of IRF4 in T and B cells is strongly induced by antigen receptor signaling.
Localisation
Nucleus.
Function
In the immune system, IRF4 is critical for development and maturation of multiple lineages of blood cells. In T cells development, IRF4 is essential for the differentiation of Th1, Th2, Th9, Th17 and T reg subsets. In B lymphocytes, IRF4 promotes light chain rearrangement and transcription and is critical for B cell development at the pre-B stage. IRF4 antagonizes Notch signaling and limits the size of marginal zone B cells (Simonetti et al., 2013) .
In addition, IRF4 is essential for class-switching and plasma cell differentiation. In B cells, IRF4 interacts with Ets family of trancription factor (PU.1/spi-B) through EICE site whereas in T cells, IRF4 interacts with AP-1 family of trancription factor (BATF) through AICE site. Also, IRF4 is required for the differentiation of dendritic cells (DCs), particularly the CD11b(+) subset (Schlitzer et al., 2013) . In macrophages, IRF4 promotes the differentiation and polarisation to the M2 subtype also known as the tumor associated macrophages. Recent studies have identified a role of IRF4 in adipocyte biology. IRF4 has been shown to regulate enzymes required for lipolysis in adipocytes. Therefore, an adipocyte specific deletion of IRF4 causes enhanced lipid synthesis, dysregulated lipid homeostasis eventually leading to obesity. Interestingly, in melanocytes IRF4 was recently identified to cooperate with another transcription factor, MITF to positively regulate the expression of tyrosinase gene required for melanin synthesis. Additionally, the SNPs in the IRF4 gene locus have been identified as risk alleles for developing melanoma.
Homology
Among IRF family members, IRF4 is highly homologous to IRF8.
Mutations

Germinal
SNPs in the IRF4 gene locus have been identified in patients with chronic lymphocytic leukemia and melanoma.
Somatic
Somatic mutations in DNA binding domain of IRF4 have been identified in a small subset (1,5%) of chronic lymphocytic leukemia (CLL) patients. 
Implicated in
Multiple myeloma (MM)
Chronic lymphocytic leukemia (CLL)
Disease CLL is the most common adult leukemia in the western countries. It is a heterogeneous B-cell malignancy marked by progressive accumulation of CD5 positive mature B lymphocytes. A Genome Wide Association Study (GWAS) recently identified SNPs in the 3' UTR of IRF4 gene locus in patients with CLL. The individuals carrying the risk alleles harboring the SNPs have lower levels of IRF4 and poorer outcomes compared to individuals carrying the non-risk allele. Another study identified mutations in the DNA binding domain of IRF4 in a small subset (1,5%) of CLL cases. More recently, using two distinct murine genetic models, it has been shown that low levels of IRF4 are causally related to the development of CLL. Prognosis CLL patients with low levels of IRF4 have aggressive disease course and poor prognosis.
Cytogenetics
Although reciprocal translocations are extremely rare in CLL, a translocation disrupting IRF4 gene locus t(1;6)(p35.3;p25.2) was identified in a small subset of CLL patients with aggressive disease. Hybrid/Mutated gene Mutations in the DNA binding domain of IRF4 with a yet undefined function in B cells were identified in a small subset of CLL cases. Oncogenesis The precise mechanism for oncogenesis of CLL in presence of low levels of IRF4 is not yet known.
Diffused large B cell lymphoma (DLBCL)
Disease Diffuse large B cell lymphoma represents a heterogeneous malignancy that arises spontaneously or develop from pre-existing leukemia. On the basis of gene expression profiling DLBCL is divided into three distinct subtypes namely the germinal center subtype (GCB), the activated B cell subtype (ABC) and the mediastinal subtype. The three subtypes presumably arise from three distinct B cell subtypes. IRF4 is primarily overexpressed in the ABC type of DLBCL while GCB subtype is marked by lower expression of IRF4. Prognosis IRF4 is overexpressed in the ABC type DLBCL which is most aggressive form of DLBCL and have poorer patient outcomes compared to other subtypes. Cytogenetics IRF4 is overexpressed in a small group of patients with a reciprocal translocation between IgG locus and the IRF4 t(1;6)(p35.3;p25.2). The patients carrying the translocation primarily belong to GCB or follicular lymphoma grade 3 type is associated with favorable patient outcomes. Oncogenesis IRF4 induces the expression of transcription factor Blimp-1 and directly suppresses the expression of Bcl-6 to allow terminal differentiation of activated B cells to plasma cells. However, this molecular network is short circuited in ABC DLBCL by recurrent mutational inactivation of Blimp-1. Additionally, mutations located in the promoter region of Bcl-6 that disrupt the IRF4 binding sites and leads to enhanced expression of Bcl-6 were identified in a small group of patients. These genetic events disrupt the molecular network required for plasma cell differentiation. However, the precise functional role of IRF4 in pathogenesis of ABC type DLBCL is not well defined. 
Hodgkins lymphoma (HL)
Primary cutaneous anaplastic large cell lymphoma (C-ALCL)
Disease Primary cutaneous anaplastic large cell lymphoma (C-ALCL) is a T cell lymphoma with an indolent disease course and presence of tumor lesions in the skin. The lesions in C-ALCL almost never spread extra-cutaneously and often regress spontaneously. IRF4 is overexpressed in C-ALCL but not in the more aggressive form of the disease known as peripheral T cell lymphoma not otherwise specified (PTCL-NOS). The overexpression of IRF4 in some cases is associated with a recurrent translocations a subset of them placing the IRF4 gene next to the T cell receptor alpha (TCRA) promoter t(6;14)(p25;q11.2). Other translocations identified do not involve TCRA. Cytogenetics IRF4 is translocated primarily in the C-ALCL however the precise breakpoints are not defined. In a small subset of the cases with translocations IRF4 is juxtaposed to the TCRA locus t(6;14)(p25;q11.2).
B cell acute lymphoblastic leukemia (B-ALL)
Disease B cell acute lymphoblastic leukemia (B-ALL) is a B cell malignancy derived from early B cells. IRF4 is shown to play a tumor suppressive role in B-ALL. IRF4 is shown to suppress the oncogenesis of both BCR-ABL and c-myc induced B-ALL. Oncogenesis IRF4 inhibits B-ALL by regulating the expression of negative regulators of cell cycle p27.
IRF4 (interferon regulatory factor 4)
Shukla V, Lu R Atlas Genet Cytogenet Oncol Haematol. 2014; 18(9) Chronic myeloid leukemia (CML) Disease Chronic myeloid leukemia (CML) is a myeloproliferative disorder marked by clonal expansion of granulocytes. It is associated with a hallmark translocation and presence of a fusion BCR-ABL protein in majority of patients. IRF4 is shown to be underexpressed in CML patients along with its highly homologous family member IRF8. However the functional role of IRF4 in CML is not well characterized.
Virus implicated malignancies
Disease Viruses like Epstein Barr virus (EBV), human T cell leukemia virus-1 (HTLV1) and Kaposi Sarcoma associated herpes virus (KSHV/HHV-8) are implicated in B cell malignancies, adult T cell leukemia (ATL) and primary effusion lymphoma (PEL) respectively. The proteins encoded by these viruses, directly or indirectly activate NF-kB signaling which in turn activates the expression of IRF4. As a result IRF4 is overexpressed in these virus implicated malignancies. The knockdown of IRF4 in EBV transformed B cells lead to downregulation of genes involved in cellular proliferation. The role of IRF4 in HTLV-1 induced ATL is not clear however few reports indicate its involvement in regulation of cell cycle associated genes. The role of IRF4 in KSHV induced kaposi's sarcoma and PEL is ambiguous. KSHV encodes viral homologs of cellular IRFs called vIRFs. The vIRF4 is shown to inhibit the function of cellular IRF4 leading to induction of lytic cycle for KSHV replication. Oncogenesis The role of IRF4 in these viral implicated malignancies is still unclear. However, the activation status of NF-kB by these viruses invariably co-relates with IRF4 expression in these cells.
Skin cancer
Disease
Skin cancer is associated with malignant or nonmalignant lesions on the skin. Based on the cell of origin, skin cancer can be divided into three types: basal cell carcinoma, squamous cell carcinoma and melanoma. The differential skin pigmentation induced by melanin production alters the risk for skin cancer. Particularly individuals with light skin tones and hence low melanin secretion are more predisposed to developing skin cancer. Until recently there were no known reports for a role of IRF4 in melanocytes. However recently, SNPs identified in the IRF4 gene locus have been shown to be associated with skin pigmentation and the risk for developing skin cancer. The SNP identified in the screen map to a putative enhancer region in the IRF4 gene locus. Oncogenesis Recently, the SNP identified in IRF4 locus were demonstrated to decrease IRF4 expression by disruption of specific transcription factor binding sites. Additionally, IRF4 corroborates with micropthalmia associated transcription factor (MITF) to regulate the expression of enzyme tyrosinase responsible for melanin production. These studies point towards a critical role for IRF4 in melanocyte biology and also its association with skin cancer.
